IMMUNOSTIMULATION WITH POLYBACTERIAL LYSATE (URIVAC®) IN PREVENTING RECURRENT LOWER URINARY TRACT INFECTIONS


Authors: Miroslav Hanuš 1;  Michaela Matoušková 1;  Vlasta Králová 1;  Jan Hiblbauer, jr. 2;  Jakub Szewczyk 3;  Radek Sýkora 3;  Riad Sabra 4;  Peter Tomaštík 5;  Jiří Paseka 6
Authors‘ workplace: Urocentrum, Praha 1;  Sanus, Hradec Hrálové 2;  Urologické oddělení, FN Ostrava 3;  Urolog, Praha 4;  Urohelp, Brno 5;  Leading Clinical Research 6
Published in: Ces Urol 2015; 19(1): 33-43
Category:

Overview

In European countries, including the Czech Republic, urinary tract infections (UTIs) have long occupied the second place in the incidence of infectious diseases in the population, thus representing a major socioeconomic problem. Along with respiratory infections, they are the major contributors to the prescription of antimicrobial agents. Extensive antimicrobial therapy is one of the most important causes of increased bacterial resistance. Immunostimulation is a possible way of preventing recurrent lower urinary tract infections and reducing the consumption of antimicrobial agents.

A prospective multicentre study evaluated the clinical efficacy, tolerability, and benefit to treatment of recurrent infections with the immunostimulatory drug Urivac®.

The number of attacks of lower urinary tract infections following immunostimulation reduced significantly both during its course and after its cessation (p = 2.2 x 10–16). During immunostimulation, 85 % of patients were symptom-free, and during subsequent follow-up it was 70.8 %. There was associated with a reduction in the number of the antimicrobial agents administered. Subjective improvement persisted in more than 57 % even after treatment cessation. Microbiological response reached 77 %; it decreases with increased time from treatment cessation. In the case of exacerbations, uropathogenic flora was detected in 61 %. Adverse effects in two patients led to early termination of the therapeutic regimen.

KEY WORDS:
Immunomodulatory therapy, bacterial lysate, recurrent urinary tract infection (RUTI).


Sources

1. Bystroň J. Recidivující infekce a možnosti jejich ovlivnění imunomodulací. Med. Praxi 2010; 7(3): 115–121.

2. Bartoníčková K. Uroinfekce. Galén 2000, 79 s.

3. Petanová J. Imunostimulační terapie, rizika, přínosy, současné možnosti. Interní Med. 2011; 13 (9): 343–346.

4. Kotulová D. Návrh na štandardné metódy prípravy baktériových imunomodulačných stock vakcín. Acta Hygienica, Epidemiologica et Microbiologica, příloha č. 2, 1991. Praha: Inst. hygieny a epidemiologie.

5. Conti-Freitas LC, Foss-Freitas MC, et al. Effect of BCG stimulus on proinflammatory cytokine production in laryngeal cancer. Cancer Immunol Immunother. 2009; 58: 25–29.

6. Fučíková T. Imunomodulace. In: Klinická imunologie v praxi (2. vydání). Praha: Galén; 1997: 280–318.

7. Bystroň J. Bakteriální imunomodulátory – současné použití v klinické praxi. Remedia 2010; 20: 298–304.

8. Petanová J. Imunostimulační léčba v urologii. Urol. praxi, 2013; 14(3): 100–103.

9. Bartoníčková K. Komentář k článku Petanové J. „Imunostimulační léčba v urologii“. Urol. praxi, 2013; 14(3): 103.

10. Bauer HW, Alloussi S, Egger G, et al. A Long-Term, Multicenter, Double-Blind Study of an Escherichia Coli Extract (OM-89) in Female Patients with Recurrent Urinary Tract Infections. European Urology, 2005; 47: 542–548.

11. Grabe M, Bartoletti R, Bjerklund-Johansen TE, et al. Guidelines on Urological Infections. European Association of Urology 2014. http://uroweb.org/guideline/urological-infections/

12. Karen I, Kolek V, Matoušková M, et al. Antibiotická terapie respiračních, močových a kožních infekcí v ordinaci všeobecného praktického lékaře. Doporučené diagnostické a terapeutické postupy pro všeobecné praktické lékaře, aktualizace 2014: 31.

13. Ha US, CHo YH. Immunostimulation with Escherichia coli extrakt: prevention of recurrent urinary tract infections. International J Antimicrob Agent 2008; 31 (Suppl 1): S63–67.

14. Bystroň J. Využití bakteriálních lyzátů v klinické praxi. Interni Med. 2012; 14 (1): 12–17.

15. Rugendorff EW. Immunological therapy of recurrent urinary tract infections with immunoactive E. coli fractions in women. Intern. Urogynecol. J. 1992; 3: 174–184.

16. Sabra R. Vezikoureterální reflux, refluxová nefropatie a močové infekce. Praha 1995, Maxdorf-Jessenius.

17. Cruz F, Dambros M, Naber KG, et al. Recurrent Urinary Tract Infections: Uro-Vaxom, a New Alternative. European Urology 2009; Supplements, 8: 762–768.

18. Bartoníčková K. Léčení infekcí močových cest v éře narůstající rezistence na antibiotika. Je imunomodulace smysluplná? Ces Urol, 2009; 1(13): 19–20.

19. Rejchrt M, Havlová K, Kříž J. Prevence recidivujících uroinfekcí intravezikální instilací kyseliny hyaluronové a chondroitinsulfátu u pacientů po míšním poranění. Urol. praxi 2015; 16(1): 43.

20. Proč užívat URIVAC. http://www.bioveta.cz/cs/humanni-divize/urivac.

Labels
Paediatric urologist Nephrology Urology

Article was published in

Czech Urology

Issue 1

2015 Issue 1

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account